Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study

Trial Profile

Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Angina pectoris
  • Focus Adverse reactions; Registrational
  • Sponsors IRIS
  • Most Recent Events

    • 23 Jul 2012 Planned end date changed from 4 Aug 2014 to 30 Sep 2015 as reported by ISRCTN: Current Controlled Trials record.
    • 14 Jul 2012 Planned end date changed from 1 May 2014 to 4 Aug 2014 as reported by European Clinical Trials Database record.
    • 14 Jul 2012 IRIS, Servier added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top